MSOPPE

Discontinued Product

MSOPPE (Cat. No. 0804) has been withdrawn from sale for commercial reasons.
Description: Group II/group III mGlu antagonist. More selective for group II than group III
Chemical Name: (RS)-a-Methylserine-O-phosphate monophenyl ester
Datasheet
Citations
Reviews
Literature (4)

Biological Activity for MSOPPE

mGlu receptor antagonist, slightly more selective for group II vs group III mGlu receptors. On primary afferent terminals in neonatal rat spinal cord, shows 3-fold greater selectivity for the (1S,3S)-ACPD-sensitive presynaptic receptor over the L-AP4-sensitive mGlu receptor (apparent KD values are 73 μM and 221 μM respectively). Has no activity on postsynaptic mGlu receptors or ionotropic glutamate receptors on neonatal rat motoneurones.

Technical Data for MSOPPE

M. Wt 275.2
Storage Store at RT
CAS Number 170984-70-0

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for MSOPPE

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for MSOPPE

References are publications that support the biological activity of the product.

Thomas et al (1996) α-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology 35 637 PMID: 8887973

Jane et al (1996) Phosphono substituted amino acids as selective metabotropic glutamate receptor antagonists. Phosphorous, Sulphur and Silicon 109-110 313

Thomas et al (1995) Serine-O-phosphate derivatives as novel, potent and selective metabotropic glutamate receptor (mGluR) antagonists. Soc.Neurosci.Abstr. 21 P616

View Related Products by Product Action

View all Glutamate (Metabotropic) Group II Receptor Antagonists

Keywords: MSOPPE, MSOPPE supplier, Glutamate, (Metabotropic), Group, II, Receptors, 0804, Tocris Bioscience

Citations for MSOPPE

Citations are publications that use Tocris products.

Currently there are no citations for MSOPPE.

Reviews for MSOPPE

There are currently no reviews for this product. Be the first to review MSOPPE and earn rewards!

Have you used MSOPPE?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.